Combination of local rose bengal and systemic immunomodulative therapies for enhanced treatment of cancer

A method of treatment of a solid tumor cancer in a human comprising administering a therapeutically effective amount of:

• (1) an intralesional chemoablative pharmaceutical composition to elicit ablation of at least one cancerous tumor;
• and (2) a therapeutically effective amount of a systemic immunomodulatory anticancer agent that is a systemic inhibitor of immune system down-regulation comprising anti-CTLA-4 antibodies, anti-PD-L1 antibodies, or anti-PD-1 antibodies, in a combination therapeutic regimen,
• wherein said intralesional chemoablative pharmaceutical composition comprises an intralesional (IL) chemoablative agent comprising rose bengal (4,5,6,7-tetrachloro-2′,4′,5′,7′-tetraiodofluorescein) in an appropriate pharmaceutical composition, including a 0.1% (w/v) up to about 20% (w/v) aqueous solution of rose bengal, or a physiologically acceptable salt of rose bengal, said intralesional chemoablative pharmaceutical composition being administered intralesionally into said at least one cancerous tumor at about 0.1 mL/cc lesion volume to about 2 mL/cc lesion volume.

A method of treatment of a solid tumor cancer in a human comprising separately administering a therapeutically effective amount of:

• (1) an intralesional chemoablative pharmaceutical composition to elicit ablation of at least one cancerous tumor;
• and (2) a therapeutically effective amount of a systemic immunomodulatory anticancer agent that comprises anti-CTLA-4 antibodies, anti-PD-L1 antibodies, or anti-PD-1 antibodies, wherein said intralesional chemoablative pharmaceutical composition comprises an intralesional (IL) chemoablative agent comprising a halogenated xanthene in an appropriate pharmaceutical composition, including a 0.1% (w/v) up to about 20% (w/v) aqueous solution of the halogenated xanthene or mixtures thereof, or a physiologically acceptable salt of the halogenated xanthene.